J. Blokken PhD, PharmD

Highlights from the International Conference on Malignant Lymphoma (ICML)

SUMMARY

The 17^th International Conference on Malignant Lymphoma (ICML) was held in Lugano, Switzerland from 13–17^th June, 2023. Once more, the program addressed the state-of-the-art on the biology, pathology and management of lymphoid neoplasms through a broad plethora of general sessions, ‘Focus-on’ and educational sessions. Below, we summarise some of the key sessions in the field of aggressive lymphomas, Hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukaemia, and follicular lymphoma.

(BELG J HEMATOL 2023;14(7):308–12)

Real-world evidence in the treatment of high-risk acute myeloid leukemia

Based on the results of the phase III Study 301, Vyxeos Liposomal was approved in Europe in 2018 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukaemia (AML) and AML with myelodysplasia-related changes. Since then, various real-world studies have assessed the safety and efficacy of this drug in routine clinical practice. The real-world evidence that was obtained not only supports the results from the clinical trial but also addresses an important data gap in terms of the achievement of minimal residual disease (MRD) negativity. Below we summarize the real-world experience with Vyxeos Liposomal in patients with high-risk AML.

Journal scan

SUMMARY

In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.

(BELG J HEMATOL 2023;14(6):265–9)

Highlights in acute lymphoblastic leukaemia

SUMMARY

The EHA 2023 congress was not only the opportunity to present updates on immune therapeutic treatments in acute lymphoblastic leukaemia (ALL), but also was also the occasion to present some clinical updates of important clinical studies in this setting. Below, we will discuss some of the key take-away messages from both sessions.

(BELG J HEMATOL 2023;14(5):226–9)

Highlights in acute myeloid leukaemia and myelodysplastic syndromes

SUMMARY

EHA 2023 again featured a plethora of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In this article, we will highlight some of the most promising data with regard to AML clinical studies, novel combinations in the treatment of AML and risk stratification. Furthermore, we will discuss some important clinical updates in the field of MDS.

(BELG J HEMATOL 2023;14(5):221–5)

Navigating secondary acute myeloid leukaemia in 2023

SUMMARY

In 2022, both the World Health Organisation (WHO) and International Consensus Classification (ICC) have updated the classification of acute myeloid leukaemia (AML) in order to reflect recent advances in disease understanding. In terms of secondary AML, there are now new definitions of therapy-related AML and AML with myelodysplasia-related changes. Furthermore, it is becoming more and more clear that also older patients benefit from intensive chemotherapy, followed by haematopoietic stem cell transplantation. With regard to Vyxeos Liposomal, a multitude of real-world studies could confirm the safety and efficacy that was observed in the randomised, phase III Study 301.

Long-term outcomes of isatuximab in high-risk multiple myeloma

SUMMARY

Patients with high-risk multiple myeloma (HRMM) represent a subgroup of 15–20% of MM patients and have reduced survival rates.^1,2 The current classification of HRMM includes the presence of at least one mutation associated with poor prognosis, such as del(17p), t(4;14), or t(14;16), and was extended to include 1q21+ in the second revision of the Revised International Staging System.^3,4 In recent years, new diagnostic and prognostic factors have emerged, making the HRMM disease profile even more complex.^5,6 As the prevalence of MM continues to increase globally, and the disease is still incurable, extensive research is being conducted to improve current treatment strategies.⁷ One potential improvement is the addition of anti-CD38 antibodies, such as isatuximab or daratumumab, to existing treatment regimens. At EHA 2023, Prof. Dr. Thierry Facon (Lille University Hospital, France) presented the long-term results of isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) in patients with 1q21+ status.⁸ Prof. Dr. Philippe Moreau (University Hospital of Nantes, France) discussed the results of Isa-Kd and isatuximab in combination with pomalidomide-dexamethasone (Isa-Pd) in MM patients with an ultra-high-risk profile.⁹ In addition, new data demonstrated that isatuximab with weekly Kd can be used as an appropriate and more convenient salvage regimen in patients with relapsed and/or refractory multiple myeloma (RRMM).¹⁰